Jakus Zoltán, Németh Tamás, Verbeek J Sjef, Mócsai Attila
Department of Physiology, School of Medicine, Semmelweis University, Budapest, Hungary.
J Immunol. 2008 Jan 1;180(1):618-29. doi: 10.4049/jimmunol.180.1.618.
Immune complex-induced activation of neutrophils through cell surface FcRs plays a central role in the pathogenesis of autoimmune inflammatory diseases. These diseases are often modeled using genetically modified mice. However, in contrast to the number of studies on human cells, the identity of FcRs involved in immune complex activation of murine neutrophils is at present unknown. Furthermore, little is known about the cellular functions mediated by the recently identified murine FcgammaRIV. In this study, we tested the identity of FcRs involved in the activation of neutrophils by plate-bound immune complexes, using various knockout mouse strains, function-blocking mAbs, or the combination of both approaches. Activation of murine neutrophils by immobilized IgG immune complexes was abrogated in FcR gamma-chain-deficient cells, but not by the single or combined deficiency of the gamma-chain-associated FcgammaRI and FcgammaRIII, or by blocking Abs against either FcgammaRIII or FcgammaRIV alone. However, treatment of FcgammaRIII-deficient neutrophils with FcgammaRIV-blocking Abs or simultaneous blocking of FcgammaRIII and FcgammaRIV in wild-type cells completely inhibited the immune complex-induced cellular responses. In parallel studies, activation of human neutrophils by immobilized immune complexes was abrogated by blocking Abs against either FcgammaRIIA or FcgammaRIIIB alone. Taken together, neutrophil activation by immobilized immune complexes requires the murine FcgammaRIII/FcgammaRIV or the human FcgammaRIIA/FcgammaRIIIB molecules. Although both of the two human receptors are required for this response, the two murine receptors play overlapping, redundant roles. These results promote our understanding of autoimmune diseases and identify an IgG-dependent cellular function of FcgammaRIV.
免疫复合物通过细胞表面Fc受体诱导中性粒细胞活化,在自身免疫性炎症疾病的发病机制中起核心作用。这些疾病通常使用基因改造小鼠进行建模。然而,与对人类细胞的研究数量相比,目前尚不清楚参与免疫复合物激活小鼠中性粒细胞的Fc受体的身份。此外,对于最近鉴定出的小鼠FcγRIV介导的细胞功能知之甚少。在本研究中,我们使用各种基因敲除小鼠品系、功能阻断单克隆抗体或两种方法的组合,测试了参与板结合免疫复合物激活中性粒细胞的Fc受体的身份。在FcRγ链缺陷细胞中,固定化IgG免疫复合物对小鼠中性粒细胞的激活被消除,但γ链相关的FcγRI和FcγRIII的单一或联合缺陷,或单独针对FcγRIII或FcγRIV的阻断抗体均未消除。然而,用FcγRIV阻断抗体处理FcγRIII缺陷的中性粒细胞,或在野生型细胞中同时阻断FcγRIII和FcγRIV,完全抑制了免疫复合物诱导的细胞反应。在平行研究中,固定化免疫复合物对人类中性粒细胞的激活可通过单独针对FcγRIIA或FcγRIIIB的阻断抗体消除。综上所述,固定化免疫复合物激活中性粒细胞需要小鼠的FcγRIII/FcγRIV或人类的FcγRIIA/FcγRIIIB分子。虽然这两种人类受体都参与了这一反应,但这两种小鼠受体发挥着重叠、冗余的作用。这些结果促进了我们对自身免疫性疾病的理解,并确定了FcγRIV的一种IgG依赖性细胞功能。